List of Excipients in API dapagliflozin and saxagliptin
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing dapagliflozin and saxagliptin
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | QTERN | dapagliflozin and saxagliptin | 0310-6780 | ANHYDROUS LACTOSE | 2029-12-16 |
| AstraZeneca Pharmaceuticals LP | QTERN | dapagliflozin and saxagliptin | 0310-6780 | CELLULOSE, MICROCRYSTALLINE | 2029-12-16 |
| AstraZeneca Pharmaceuticals LP | QTERN | dapagliflozin and saxagliptin | 0310-6780 | CROSCARMELLOSE SODIUM | 2029-12-16 |
| AstraZeneca Pharmaceuticals LP | QTERN | dapagliflozin and saxagliptin | 0310-6780 | FERROUS OXIDE | 2029-12-16 |
| AstraZeneca Pharmaceuticals LP | QTERN | dapagliflozin and saxagliptin | 0310-6780 | MAGNESIUM STEARATE | 2029-12-16 |
| AstraZeneca Pharmaceuticals LP | QTERN | dapagliflozin and saxagliptin | 0310-6780 | POLYETHYLENE GLYCOL 400 | 2029-12-16 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for dapagliflozin and saxagliptin
Excipient focus: ANHYDROUS LACTOSE
dapagliflozin and saxagliptin drug variants containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
dapagliflozin and saxagliptin drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
dapagliflozin and saxagliptin drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROUS OXIDE
dapagliflozin and saxagliptin drug variants containing FERROUS OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing FERROUS OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
dapagliflozin and saxagliptin drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 400
dapagliflozin and saxagliptin drug variants containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
dapagliflozin and saxagliptin drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
dapagliflozin and saxagliptin drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
dapagliflozin and saxagliptin drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
dapagliflozin and saxagliptin drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | dapagliflozin and saxagliptin | 0310-6780 |
| >Company | >Ingredient | >NDC |
dapagliflozin and saxagliptin drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
